Trending

endocrinology

Samsung Bioepis signs R&D agreement with Takeda

Samsung Bioepis signs R&D agreement with Takeda

South Korean firm looking to develop novel drugs

X

Samsung Bioepis signs R&D agreement with Takeda

https://pharmaphorum.com/news/samsung-bioepis-signs-rd-agreement-takeda/

Growth hormone could be filed without further trials, says OPKO

Growth hormone could be filed without further trials, says OPKO

Drug could be filed after “outlier” analysis.

X

Growth hormone could be filed without further trials, says OPKO

https://pharmaphorum.com/news/opko-growth-hormone-filed-without-trials/

OPKO weekly growth hormone jab fails in phase 3

OPKO weekly growth hormone jab fails in phase 3

US biotech OPKO Health has said it will continue with clinical development of its long-acting human growth hormone

X

OPKO weekly growth hormone jab fails in phase 3

https://pharmaphorum.com/news/opko-weekly-growth-hormone-jab-fails-in-phase-3/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com